NCT05605951
Who may be able to join
Who might be able to join this trial:
- You are experiencing your first-ever episode of optic neuritis (inflammation of the optic nerve)
- Your vision symptoms started no more than 30 days ago
- You are 18 years of age or older
- You are able to read, understand, and sign a written consent form
Who may not be able to join:
- You cannot have an MRI scan (for example, due to having certain metal implants or devices in your body)
- You have previously been diagnosed with a demyelinating disease (a condition where the protective covering of nerves is damaged, such as multiple sclerosis)
- You have been diagnosed with another type of optic nerve disease, such as one caused by genetics, infection, inflammation from conditions like sarcoidosis, toxic substances, or other infiltrative causes (confirm with trial site)
- You are pregnant at the time of joining the trial
- You have other serious health conditions that the study team considers would make participation unsuitable (confirm with trial site)
- You are unable to cooperate with the study procedures for any reason
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Trial details
Where this trial is recruiting
1 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
to investigate whether MS-ON, AQP4-IgG+ON and MOG-IgG+ON patients treated with early high-dose corticosteroids for visual loss have better visual outcomes and QoL than those with late treatment.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.